Shots:

• Insitro to receive $50M as up front- $20M as near-term operational milestones and is eligible to receive ~$2B+ as discovery- development- regulatory and commercial milestones along with royalties on sales of the therapies
• BMS will lead the clinical development- regulatory submissions- and commercialization activities. Insitro will apply its insitro Human (ISH) platform- to create iPSC derived disease models for ALS and FTD
• Insitro will apply ML-enabled therapeutics discovery capabilities to advance programs while BMS to get an option to select several targets identified by insitro to advance through clinical development and commercialization

 Ref: Businesswire | Image: BMS